Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
November 13, 2019
DEER PARK, Ill. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation .
November 6, 2019
DEER PARK, Ill. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday,
October 22, 2019
~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration Errors, Sterility Breaches, and Waste ~ DEER PARK, Ill. , Oct.

Eton
Latest Event